September 21, 2020         
One Young World and the Dutch Ministry of Foreign Affairs Announce 'Enterprise for Peace' Cohort 2021   •   Unifor raises $134,000 to aid domestic violence victims   •   Miles Christi to Ordain 1st American Priest   •   Emily Leproust, Ph.D., to Receive 2020 Rosalind Franklin Award   •   Dr. Scholl’s Shoes Wins Footwear Honor at the Accessories Council’s Design Excellence Awards for the Second Year in   •   The "Justice Ruth Bader Ginsburg Woman of Leadership Award" Legacy   •   Auden Living Announces Housing Discounts for First Responders, Military and Healthcare Workers   •   BET, National Urban League and an Expanding List of Key Impact Partners Unite on National Black Voter Day, Friday, September 18   •   Statement by Minister Monsef on the occasion of Gender Equality Week   •   Greenberg Traurig's Mary-Olga Lovett Selected as 2020 Best Mentor by Texas Lawyer   •   Crema.co’s New Coffee Matching Algorithm Guarantees the Perfect Cup   •   Canada's fisheries may be destroyed   •   HostForWeb Announces Tips For How to Talk to Younger Children About Cybersecurity   •   Campbell Appoints Camille Pierce as Chief Culture Officer   •   New Citi Impact Fund Announces First Investments   •   Helen of Troy Limited Announces Earnings Release Date, Conference Call, and Webcast for Second Quarter Fiscal Year 2021 Results   •   Publix Named Among Fortune’s Best Workplaces for Women   •   Statement by the Prime Minister on Gender Equality Week   •   Asana Named No. 8 on the 2020 Best Workplaces for Women by Great Place to Work® and Fortune   •   Ultimate Software Ranked #2 on Fortune’s Best Workplaces for Women 2020 List
Bookmark and Share

Blacks Benefiting From Targeted Cancer Therapy

 PHILDALPHIA — African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.

“This study has immediate implications for patient management. Patients with EGFR mutations have a much better prognosis and respond better to erlotinib than those who do not,” said Ramsi Haddad, Ph.D., director of the Laboratory of Translational Oncogenomics at the Barbara Ann Karmanos Cancer Institute, and assistant professor at Wayne State University School of Medicine.

Haddad’s study, which he presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, also showed that African-Americans were more likely to have mutations on exon 19, rather than exon 21, which suggests they would be even more responsive to erlotinib.

Erlotinib, currently marketed as Tarceva by Genentech, has shown remarkable benefits in non-small cell lung cancer patients with EGFR mutations. Other therapies are in development and the genetic testing is clinically available.

Previous studies had suggested that African-Americans had lower rates of EGFR mutation, which researchers had offered as a possible explanation for their generally poorer prognosis.

However, Haddad’s study was larger than previous reports. His research team observed 149 patients with non-small cell lung cancer (NSCLC), including 80 Caucasians and 69 African-Americans.

Using state-of-the-art technology that allowed for simultaneous detection of hundreds of oncogene mutations in clinical samples, they identified EGFR mutations in 20 of these patients, including 12 Caucasians and eight African-Americans. The difference was not statistically significant.

Moreover, 100 percent of the EGFR mutations in African-Americans were in exon 19, compared with only two-thirds of the mutations found in Caucasian patients. 

“It is well-documented that the incidence of lung cancer is higher among African-Americans, particularly men, and that their survival is generally poorer compared to their white counterparts,” said Haddad. “Our data suggest that African-Americans with NSCLC harbor mutations in EGFR at rates similar to whites. Thus, African ancestry should not be a factor when deciding whether to test a tumor for these mutations, as doing so could widen the disparity seen in survival. Physicians treating these patients may want to consider this new information in their treatment decisions.” 

 


STORY TAGS: BLACK , AFRICAN AMERICAN , MINORITY , CIVIL RIGHTS , DISCRIMINATION , RACISM , NAACP , URBAN LEAGUE , RACIAL EQUALITY , BIAS , EQUALITY

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News